Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT02951156
What this trial is testing

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 29
Not applicableStudy completedNCT00053157
What this trial is testing

Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+3 more
Roswell Park Cancer Institute 10
Large-scale testing (Phase 3)Study completedNCT04833114
What this trial is testing

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
GWT-TUD GmbH 306
Early research (Phase 1)Looking for participantsNCT06191887
What this trial is testing

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

Who this might be right for
B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell Lymphoma+12 more
Mayo Clinic 27
Early research (Phase 1)Active Not RecruitingNCT03853616
What this trial is testing

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

Who this might be right for
Acute Lymphoblastic Leukemia RecurrentB-cell Lymphoma RecurrentB-cell Lymphoma Refractory+2 more
Miltenyi Biomedicine GmbH 48
Testing effectiveness (Phase 2)Study completedNCT02199184
What this trial is testing

Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia

Who this might be right for
AIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+5 more
M.D. Anderson Cancer Center 14
Testing effectiveness (Phase 2)Ended earlyNCT00079443
What this trial is testing

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma
National Cancer Institute (NCI) 60
Early research (Phase 1)Study completedNCT02741388
What this trial is testing

A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP

Who this might be right for
B-cell Lymphoma
The Lymphoma Academic Research Organisation 39
Testing effectiveness (Phase 2)Looking for participantsNCT05643742
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more
CRISPR Therapeutics AG 120
Testing effectiveness (Phase 2)Study completedNCT03994913
What this trial is testing

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma
CARsgen Therapeutics Co., Ltd. 20
Early research (Phase 1)Looking for participantsNCT05773040
What this trial is testing

JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

Who this might be right for
LymphomasB-cell Lymphomas
M.D. Anderson Cancer Center 33
Very early researchNot Yet RecruitingNCT07670260
What this trial is testing

GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Large B-cell Lymphoma
Chinese PLA General Hospital 9
Testing effectiveness (Phase 2)Ended earlyNCT00281879
What this trial is testing

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersLeukemiaLymphoma+4 more
OHSU Knight Cancer Institute 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT05451810
What this trial is testing

Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaClassic Follicular Lymphoma
Genmab 184
Large-scale testing (Phase 3)Ended earlyNCT00006708
What this trial is testing

S0019 Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
SWOG Cancer Research Network 7
Testing effectiveness (Phase 2)Study completedNCT00073957
What this trial is testing

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Beth Israel Deaconess Medical Center 25
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Study completedNCT04030195
What this trial is testing

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Who this might be right for
Non-Hodgkin's Lymphoma, RelapsedChronic Lymphoid Leukemia in RelapseNon-Hodgkin's Lymphoma Refractory+6 more
Precision BioSciences, Inc. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04787263
What this trial is testing

CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

Who this might be right for
Acute Lymphoblastic LeukemiaDiffuse Large B Cell LymphomaPrimary Mediastinal Lymphoma
Bambino Gesù Hospital and Research Institute 32
Large-scale testing (Phase 3)Study completedNCT02763319
What this trial is testing

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Incyte Corporation 453
Next Page